All In Biotech

Drug Trial Radar · NCT02638337

Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause

A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Ospemifene in Patients With Moderate to Severe Vaginal Dryness, a Symptom of Vulvo-vaginal Atrophy (VVA) Due to Menopause

Last checked: Nov 20, 2026Latest source record: Apr 2, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 631 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

631

Actual

Start

Jan 26, 2016

Primary completion

Jun 23, 2017

Study completion Jul 5, 2017

Sponsor

Lead sponsor
ShionogiIndustry
Sponsor type
Industry
First posted
Dec 23, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the efficacy and safety of ospemifene 60 mg once daily (QD) compared with placebo in treatment of vulvo-vaginal atrophy (VVA) due to menopause in women with moderate to severe vaginal dryness as the most bothersome symptom (MBS) of VVA.

Conditions

  • Vaginal Dryness

Interventions

  • OspemifeneDrug

    60 mg tablet

  • PlaceboDrug

    Tablet identical to the ospemifene tablet without drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear at Week 12Time frame: Baseline and Week 12
  2. Change From Baseline in the Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear at Week 12Time frame: Baseline and Week 12
  3. Change From Baseline in the Vaginal pH at Week 12Time frame: Baseline and Week 12
  4. Change From Baseline in the Severity of Self-reported Most Bothersome Symptom (MBS) of Vaginal Dryness at Week 12Time frame: Baseline and Week 12
  5. Number of Participants With Adverse EventsTime frame: From the first dose of study drug up to 14 days after the last dose; 14 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.